Home

Robert Francomano

CIK 1797467 · Chief Commercial Officer · last filed 2024-01-25

Robert Francomano is a Chief Commercial Officer who has filed 9 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for SLS, was dated Jan 25, 2024. Across all open-market trades the lifetime net is −$72.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $510.5K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$510.5K

Companies

2

Total Filings

9

Lifetime Open-Market Net

-$72.4K

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
SLS Chief Commercial Officer 40,918 $12.47 $510.5K $0 4 2024-01-25
STEMLINE THERAPEUTICS INC (STML) Delisted Chief Commercial Officer 0 — — -$72.4K 5 2020-06-10

Recent Filings

9 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2024-01-25 SLS Grant (A) +20,000 $0 EDGAR
2023-12-08 SLS Other (J) −1,082 -$1.2K EDGAR
2023-02-03 SLS Grant (A) +12,000 $0 EDGAR
2022-03-15 SLS Grant (A) — $0 EDGAR
2020-06-10 STEMLINE THERAPEUTICS INC (STML) Delisted Mixed −200,891 $0 EDGAR
2020-05-06 STEMLINE THERAPEUTICS INC (STML) Delisted Sell (S) −272 -$3.1K EDGAR
2020-03-13 STEMLINE THERAPEUTICS INC (STML) Delisted Sell (S) −1,266 -$6.3K EDGAR
2020-02-14 STEMLINE THERAPEUTICS INC (STML) Delisted Mixed +100,875 -$34.0K EDGAR
2020-01-03 STEMLINE THERAPEUTICS INC (STML) Delisted Sell (S) −2,670 -$28.9K EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.